menu search

Revive therapeutics receives orphan drug designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for ...

February 16, 2022, 7:30 am

Revive therapeutics receives orphan drug designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for ...

February 16, 2022, 7:30 am

Longeveron: speculative biotech worth a look on rare disease, aging, and alzheimer's focuses

Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B ...

February 14, 2022, 10:01 pm

Longeveron: speculative biotech worth a look on rare disease, aging, and alzheimer's focuses

Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B ...

February 14, 2022, 10:01 pm

Longeveron: speculative biotech worth a look on rare disease, aging, and alzheimer's focuses

Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B ...

February 14, 2022, 10:01 pm

Gamida cell shares surge on rolling omidubicel marketing application in us

Gamida Cell Ltd GMDA has initiated the Biologics License Application (BLA) rolling submission process with the FDA for omidubicel, in patients with...

February 9, 2022, 12:54 pm

Gamida cell shares surge on rolling omidubicel marketing application in us

Gamida Cell Ltd GMDA has initiated the Biologics License Application (BLA) rolling submission process with the FDA for omidubicel, in patients with...

February 9, 2022, 12:54 pm

Gamida cell shares surge on rolling omidubicel marketing application in us

Gamida Cell Ltd GMDA has initiated the Biologics License Application (BLA) rolling submission process with the FDA for omidubicel, in patients with...

February 9, 2022, 12:54 pm

Davita's (dva) collaboration to aid in kidney care needs

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and ...

January 26, 2022, 12:17 pm

Davita's (dva) collaboration to aid in kidney care needs

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and ...

January 26, 2022, 12:17 pm

Davita's (dva) collaboration to aid in kidney care needs

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and ...

January 26, 2022, 12:17 pm

Fda holds mustang bio's gene therapy ind for compromised immune system disorder

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru...

January 25, 2022, 7:10 am

Fda holds mustang bio's gene therapy ind for compromised immune system disorder

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru...

January 25, 2022, 7:10 am

Fda holds mustang bio's gene therapy ind for compromised immune system disorder

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru...

January 25, 2022, 7:10 am

Fda gives nod to tscan therapeutics' early-stage trial of tsc-100 in hematologic malignancies

The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies p...

January 24, 2022, 12:30 pm

Fda gives nod to tscan therapeutics' early-stage trial of tsc-100 in hematologic malignancies

The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies p...

January 24, 2022, 12:30 pm

Fda gives nod to tscan therapeutics' early-stage trial of tsc-100 in hematologic malignancies

The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies p...

January 24, 2022, 12:30 pm

Omeros submits response to fda regarding narsoplimab application in hsct-tma

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell ...

January 20, 2022, 6:54 am

Omeros submits response to fda regarding narsoplimab application in hsct-tma

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell ...

January 20, 2022, 6:54 am

Omeros submits response to fda regarding narsoplimab application in hsct-tma

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell ...

January 20, 2022, 6:54 am


Search within

Pages Search Results: